AQP12A: A Potential Drug Target and Biomarker for Various Diseases

Target Name: AQP12A

NCBI ID: G375318

AQP12A

AQP12A: A Potential Drug Target and Biomarker for Various Diseases

A protein known as AQP12A (AQP-12) has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. This protein plays a crucial role in various physiological processes in the body, including cell signaling, blood vessel formation, and wound healing. Its unique structure and function make it an attractive target for drug development.

Structure and Function

AQP12A is a transmembrane protein that forms part of the AQP family. This family is characterized by the presence of a unique C-terminal region that contains a glycosylated region and a transmembrane region. The transmembrane region is responsible for the protein's unique structure and function.

AQP12A has a molecular weight of approximately 120 kDa and a pre-folds length of 12.5 kDa. Its transmembrane region is composed of four尾-helices, each of which is responsible for different functions. The first 尾-helix is 鈥嬧?媔nvolved in the protein's stability and functions as a critical structural unit. The second 尾-helix is 鈥嬧?媔nvolved in the protein's association with various signaling pathways, including the TGF-β pathway. The third 尾-helix is 鈥嬧?媔nvolved in the protein's interaction with other proteins, including the FBN1 protein. The fourth 尾-helix is 鈥嬧?媔nvolved in the protein's anchorage to the cell membrane.

AQP12A functions as a negative regulator of the TGF-β pathway. This pathway is involved in various cellular processes, including cell growth, differentiation, and wound healing. In cancer, the TGF-β pathway is often activated, leading to the development of various types of cancer. Therefore, inhibiting the TGF-β pathway has become a major focus of cancer research.

AQP12A has been shown to play a negative role in the TGF-β pathway. Studies have shown that AQP12A can inhibit the activity of the TGF-β receptor, leading to the downregulation of TGF-β signaling. This has implications for the development of TGF -尾 inhibitors as potential drugs for cancer treatment.

Another function of AQP12A is its role in blood vessel formation. The AQP family plays a crucial role in the regulation of blood vessel formation and the maintenance of blood pressure. AQP12A is involved in the regulation of the vascular endothelial growth factor (VEGF) receptor, which is a critical factor in blood vessel formation.

VEGF is a transmembrane protein that is involved in the regulation of various cellular processes, including cell growth, angiogenesis, and tissue repair. In cancer, the VEGF receptor is often activated, leading to the development of various types of cancer. Therefore, inhibiting the VEGF receptor has become a major focus of cancer research.

AQP12A has been shown to play a positive role in the regulation of VEGF receptor signaling. Studies have shown that AQP12A can enhance the activity of the VEGF receptor, leading to increased blood vessel formation and cancer growth. This has implications for the development of VEGF inhibitors as potential drugs for cancer treatment.

In addition to its functions in cell signaling and blood vessel formation, AQP12A is also involved in the regulation of wound healing. The AQP family plays a crucial role in the regulation of cell migration and the formation of new tissues during the wound healing process.

AQP12A is involved in the regulation of the wound healing factor (WGF) signaling pathway. WGF is a transmembrane protein that is involved in the regulation of various cellular processes, including cell growth, differentiation, and tissue repair.

Protein Name: Aquaporin 12A

Functions: Aquaporins facilitate the transport of water and small neutral solutes across cell membranes

The "AQP12A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AQP12A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets